APNIMED - AD109 GENERALLY WELL-TOLERATED IN PHASE 3 TRIALS WITH COMMON ADVERSE EVENTS DRY MOUTH, INSOMNIA, NAUSEA

Reuters · 3d ago

Please log in to view news